The Latest Breaking News from Organon

Unintended pregnancy remains a significant global health issue. A recent UNFPA report suggesting nearly half of all pregnancies, totaling 121 million each year worldwide, are unintended and more than 160 million women have limited access to contraceptives.

Upgrades

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Upgrades

'Several diversity, equity, and inclusion demographic factors already impact the global economy,' Bank of America analysts say.

Organon easily beat first-quarter expectations Thursday despite a dive for its flagship product, Nexplanon, and OGN stock popped.

 

Biotech stock Amphastar hit a record high Friday after U.S. officials approved its generic version of an Organon infertility drug.

Organon & Co (NYSE: OGN) 

Ella Holley thought the painful red rash was caused by her unhealthy lifestyle of alcohol and late nights

Ella Holley initially thought the angry red blotches had been caused by the unhealthy student lifestyle, but is now trying to raise awareness around the potential side effects of taking the contraceptive pill